Inmed Pharmaceuticals Inc (INM) Institutional Ownership & 13F Filings (Q2 2026)

INM ranks #8397 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

20 institutions disclose a position in INM, but none treat it as a major bet — even Squadron Capital Management LLC, its most concentrated holder, allocates just 0.2% of its own portfolio to it.

INM is down 1.8% today, but institutions show net buying of $4.6M this quarter — a divergence between today's price move and the underlying institutional flow.

INM reported a net loss of $12.6M over the trailing twelve months.

• Not yet profitable — net loss of $12.6M over the trailing twelve months
• Revenue declined 6.7% year over year
• Net income declined year over year, from -$8.2M to -$12.6M
• Operating cash flow was negative, using $8.6M in cash
• Current ratio of 1.37x — below the conventional 1.5x liquidity buffer
• Liabilities run 1.82x equity — within a conventional range